NCT04920903View on ClinicalTrials.gov

A Single and Multiple Ascending Dose Study of COR588

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

August 26, 2021

Primary Completion Date

April 30, 2022

Study Completion Date

April 30, 2022

Conditions
Healthy Volunteers
Interventions
DRUG

COR588

Increasing doses of COR588 will be administered for cohorts 1-4 in the single ascending dose phase and for cohorts 1-4 in the multiple ascending dose phase.

DRUG

Placebo

Placebo will be administered for cohorts 1-4 in the single ascending dose phase and for cohorts 1-4 in the multiple ascending dose phase.

Trial Locations (1)

Unknown

Nucleus Network Pty Ltd, Melbourne

Sponsors

Lead Sponsor

Cortexyme Inc.
All Listed Sponsors
lead

Cortexyme Inc.

INDUSTRY

NCT04920903 - A Single and Multiple Ascending Dose Study of COR588 | Biotech Hunter | Biotech Hunter